MediLink and Roche partner on cancer drug development

MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.

Jan 3, 2024 - 18:00

MediLink and Roche partner on cancer drug development

MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.

Read the original article

Tags:

Previous Article

EMA validates BMS’s repotrectinib application to treat cancer

PDS-01ADC by PDS Biotechnology for Colorectal Cancer: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

FDA expands GSK’s Jemperli approval for endometrial cancer

FDA expands GSK’s Jemperli approval for endometrial cancer

Aug 3, 2024

Chiesi Farmaceutici gets grant for pharmaceutical formu...

Apr 5, 2024

SOF-10 by Chugai Pharmaceutical for Gastric Cancer: Lik...

Oct 25, 2023